| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
19 auth. I. Acosta-Colman, N. Palau, J. Tornero, A. Fernández-Nebro, F. Blanco, I. González-Álvaro, J. Cañete, J. Maymó, J. Ballina, B. Fernández-Gutiérrez, ...
AIM
The present study was undertaken to replicate the association of candidate genes for anti-TNF response in rheumatoid arthritis. Candidate genes were selected from a recent genome-wide association study on anti-TNF response performed in a populat…
AIM
The present study was undertaken to replicate the association of candidate genes for anti-TNF response in rheumatoid arthritis. Candidate genes were selected from a recent genome-wide association study on anti-TNF response performed in a population from Denmark.
MATERIALS & METHODS
Genomic DNA was obtained from 315 Spanish rheumatoid arthritis patients having received an anti-TNF agent as their first biological therapy. SNPs from NR2FR2, MAP2K6, CBLN2 and PDE3A-SLCO1C1 candidate loci were genotyped.
RESULTS
The PDE3A-SLCO1C1 locus rs3794271 SNP showed a highly significant association with anti-TNF treatment response (p = 1.74 × 10⁻⁵). Combining the statistical evidence from the Spanish and Danish rheumatoid arthritis cohorts, the associated rs3794271 SNP reached a genome-wide significance level of association (p = 3.3 × 10⁻¹⁰).
CONCLUSION
The present findings establish the PDE3A-SLCO1C1 locus as a strong genetic marker of anti-TNF therapy response.
Published in
Pharmacogenomics (London)
|
31
|
6 | 2013 |
Social Media Posts